Not all hemophagocytes are created equally: Appreciating the heterogeneity of the hemophagocytic syndromes

Current Opinion in Rheumatology

Volumn 24, Issue 1, 2012, Pages 113-118

  Canna, Scott W ^a   Behrens, Edward M ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Civic Center Blvd   (United States)

Author keywords

Cytokine; Hemophagocytosis; Macrophage activation syndrome

Indexed keywords

INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOLL LIKE RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTATION; CELL TYPE; CYTOKINE PRODUCTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; MACROPHAGE ACTIVATION SYNDROME; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MICE;

EID: 82955237596     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834dd37e     Document Type: Review

References (38)

1. Grom AA, Mellins ED. Macrophage activation syndrome: Advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22: 561-566.
2. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009; 10:387-392.
3. Kuwata K, Yamada S, Kinuwaki E, et al. Peripheral hemophagocytosis: An early indicator of advanced systemic inflammatory response syndrome/ hemophagocytic syndrome. Shock 2006; 25:344-350.
4. Milner JD, Orekov T, Ward JM, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 2010; 116:2476-2483.
5. Brown DE, McCoy MW, Pilonieta MC, et al. Chronic murine typhoid fever is a natural model of secondary hemophagocytic lymphohistiocytosis. PLoS One 2010; 5:e944.
6. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-131. (Pubitemid 44958267)
7. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-1959. (Pubitemid 129515904)
8. Pachlopnik Schmid J, Cote M, Menager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010; 235:10-23.
9. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-1138. (Pubitemid 46774861)
10. Gupta A, Tyrrell P, Valani R, et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 51:402-404.
11. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146:598-604. (Pubitemid 40616243)
12. Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38:764-768.
13. Lin TF, Ferlic-Stark LL, Allen CE, et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011; 56:154-155.
14. Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol 2011; 18:609-614.
15. Wheeler RD, Cale CM, Cetica V, et al. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol 2010; 150:727-730.
16. Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011; 208:1203-1214.
17. Schaer DJ, Schaer CA, Schoedon G, et al. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006; 77:432-436. (Pubitemid 44483947)
18. Lykens JE, Terrell CE, Zoller EE, et al. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011; 118:618-626.
19. Grom AA, Villanueva J, Lee S, et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142:292-296. (Pubitemid 36338013)
20. Vastert SJ, van Wijk R, D'Urbano LE, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 2010; 49:441-449.
21. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58:2892-2896.
22. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010; 37: 967-973.
23. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010; 49:1645-1653.
24. Sato K, Misawa N, Nie C, et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011; 117:5663-5673.
25. Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 2011; 117:e151-e160.
26. Krebs P, Crozat K, Popkin D, et al. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 2011; 117:6582-6588.
27. Crozat K, Hoebe K, Ugolini S, et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: A mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med 2007; 204:853-863. (Pubitemid 46631614)
28. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011; 121:2264-2277.
29. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009; 33:231-238.
30. Guggemoos S, Hangel D, Hamm S, et al. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008; 180:438-443.
31. Yanagimachi M, Naruto T, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 2011 ; 38:769-774.
32. Marsh RA, Jordan MB, Filipovich AH. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: An important step forward. Br J Haematol 2011; 154:556-563.
33. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010; 7:415-420.
34. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011; 17:23-27.
35. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology 2011; 50:417-419.
36. Sellmer A, Stausbol-Gron B, Krag-Olsen B, et al. Successful use of infliximab in macrophage activation syndrome with severe CNS involvement. Scand J Rheumatol 2011; 40:156-157.
37. Jordan MB, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004; 104:735-743. (Pubitemid 38970567)
38. Balamuth NJ, Nichols KE, Paessler M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007; 29:569-573. (Pubitemid 47356813)